Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Boston Scientific Corporation (BSX)
USD43.25
-1.40 (-3.14%)
US NYSE S&P 500
Healthcare Medical - Devices
Address
300 Boston Scientific Way 01752-1234
Marlborough, MA, US
Marlborough, MA, US
CEO
Michael F. Mahoney
Website
bostonscientific.com
IPO
1992-05-19
CIK 885725 ISIN US1011371077
Also trades on
Frankfurt Stock Exchange · BSX.F (EUR)
London Stock Exchange · 0HOY.L (USD)
New York Stock Exchange · BSX (USD)
New York Stock Exchange · BSX-PA (USD)
Description
Boston Scientific Corporation (BSX) operates as a global leader in medical technology, specializing in the design, manufacturing, and commercialization of innovative medical devices tailored for a diverse array of interventional medical specialties across the globe. Its business is strategically organized into three principal segments: MedSurg, Rhythm and Neuro, and Cardiovascular. Within these divisions, the company provides a comprehensive portfolio of solutions addressing various gastrointestinal and pulmonary ailments, as well as urological and pelvic health concerns. This extends to advanced implantable devices for managing cardiac rhythm disorders, such as cardioverter-defibrillators, cardiac resynchronization therapy devices, and pacemakers, complemented by remote patient management systems. Furthermore, Boston Scientific offers sophisticated technologies for diagnosing and treating complex heart rate and rhythm irregularities. These encompass 3-D cardiac mapping and navigation tools, along with a suite of specialized catheters (including ablation, diagnostic, mapping, and intracardiac ultrasound types), delivery sheaths, and related accessories. Its offerings also extend to neurological conditions, providing spinal cord stimulator systems for chronic pain management, indirect decompression systems, and deep brain stimulation systems. In the realm of interventional cardiology, the company's innovations include drug-eluting coronary stent systems designed for treating coronary artery disease, products for percutaneous coronary interventions to combat atherosclerosis, and intravascular imaging catheters (such as ultrasound and fractional flow reserve devices) for assessing coronary arteries, heart chambers, and peripheral vessels. It also develops structural heart therapies. Beyond this, Boston Scientific supplies an array of stents, balloon catheters, wires, and atherectomy systems for the treatment of arterial diseases. For venous conditions, it provides thrombectomy and acoustic pulse thrombolysis systems, alongside wires and stents. Critically, the company also contributes to cancer treatment through peripheral embolization devices, radioactive microspheres, various ablation systems (including cryotherapy), and micro and drainage catheters. The organization was established in 1979 and maintains its corporate headquarters in Marlborough, Massachusetts.
News Sentiment (7d)
3 articles
- Is It Worth Investing in Boston Scientific (BSX) Based on Wall Street's Bullish Views? Zacks Investment Research
- 'Selling Winners, Buying Losers': Tech Stocks Drop as Energy Jumps to Start H2 Benzinga
- Billionaire Steve Cohen Sold Amazon and Nvidia but Loaded Up on This Beaten-Down Stock The Motley Fool
Market Cap & Enterprise Value
Merger & Acquisition History
Index membership
| Index | Added | Removed | Status |
|---|---|---|---|
| S&P 500 | 1995-02-23 | — | Active |
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD43.25
-1.40 (-3.14%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
21M
Beta
0.58
Float Shares
1.48B
Free Float %
99.5%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.55% | -5.14% | -13.29% | -31.57% | -49.33% | -50.80% | -52.40% | -8.38% | +10.27% | +104.40% | +995.71% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (44 ratings, all time)
Buy
Price Targets & DCF
Current price
43.25
Low
55.00
+27.2%
Consensus
82.90
+91.7%
Median
76.00
+75.7%
High
120.00
+177.5%
DCF (Unlevered)
98.51
+127.8%
DCF (Levered)
115.00
+165.9%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
91% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 9 | -1 |
| Buy | 23 | -1 |
| Hold | 3 | +1 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Price Target Summary
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | 11 |
70.27
+62.5%
|
| Last Quarter | 26 |
78.73
+82.0%
|
| Last Year | 62 |
100.90
+133.3%
|
| All Time | 124 |
87.56
+102.5%
|
Quality scores
Altman Z-Score
3.46
Safe zone
Piotroski F-Score
7 / 9
Strong
MOAT Score
6 / 10
Developing
Composite Rating
A-
Overall Score
4 / 5
High
DCF Score
5 / 5
High
ROE Score
4 / 5
High
ROA Score
5 / 5
High
D/E Score
2 / 5
Medium
P/E Score
2 / 5
Medium
P/Book Score
2 / 5
Medium
Operational MOAT
✗ Below peers
-
Revenue growth Medical - Devices: +11.2%+19.9% ★ Q1'26: +11.6% (vs Q1'25)
-
EPS growth Medical - Devices: +28.5%+55.2% ★ Q1'26: +99.4% (vs Q1'25)
-
FCF margin FCF growth · Medical - Devices: +30.9%+13.2% ★ Q1'26: +3.3% (vs Q1'25)
-
EBIT margin Medical - Devices: +6.2%+18.6% ★ Q1'26: +24.1% (vs Q1'25)
-
ROIC Medical - Devices: +3.3%+9.2% ★ Q1'26: +14.1% (vs Q1'25)
-
Share dilution Medical - Devices: 0.0%+0.6% Q1'26: +0.1% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Devices: -0.35×3.33× Q1'26: 2.20× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 1997 actual |
Dec 1998 actual |
Dec 1999 actual |
Dec 2000 actual |
Dec 2001 actual |
Dec 2002 actual |
Dec 2003 actual |
Dec 2004 actual |
Dec 2005 actual |
Dec 2006 actual |
Dec 2007 actual |
Dec 2008 actual |
Dec 2009 actual |
Dec 2010 actual |
Dec 2011 actual |
Dec 2012 actual |
Dec 2013 actual |
Dec 2014 actual |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 22 Rev. Ana. 17 EPS Ana. |
Dec 2027 23 Rev. Ana. 17 EPS Ana. |
Dec 2028 25 Rev. Ana. 9 EPS Ana. |
Dec 2029 12 Rev. Ana. 3 EPS Ana. |
Dec 2030 12 Rev. Ana. 3 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
1.87B
est: 1.84B (+1.7%)
|
2.23B
est: 1.98B (+12.5%)
|
2.84B
est: 2.45B (+16.1%)
|
2.66B
est: 2.61B (+1.9%)
|
2.67B
est: 2.61B (+2.6%)
|
2.92B
est: 2.67B (+9.4%)
|
3.48B
est: 3.29B (+5.6%)
|
5.62B
est: 5.54B (+1.5%)
|
6.28B
est: 6.39B (-1.7%)
|
7.82B
est: 7.50B (+4.3%)
|
8.36B
est: 7.33B (+14.0%)
|
8.05B
est: 7.46B (+8.0%)
|
8.19B
est: 8.53B (-4.0%)
|
7.81B
est: 5.16B (+51.3%)
|
7.62B
est: 5.21B (+46.2%)
|
7.25B
est: 7.05B (+2.8%)
|
7.14B
est: 6.34B (+12.6%)
|
7.38B
est: 7.02B (+5.1%)
|
7.48B
est: 7.49B (-0.2%)
|
8.39B
est: 8.36B (+0.3%)
|
9.05B
est: 9.05B (0.0%)
|
9.82B
est: 9.82B (+0.0%)
|
10.74B
est: 10.74B (0.0%)
|
9.91B
est: 10.03B (-1.2%)
|
11.89B
est: 11.87B (+0.1%)
|
12.68B
est: 12.68B (0.0%)
|
14.24B
est: 15.23B (-6.5%)
|
16.75B
est: 16.61B (+0.8%)
|
20.07B
est: 20.07B (+0.0%)
|
21.63B
21.47B – 21.89B
+7.8% YoY
|
23.36B
22.84B – 24.41B
+8.0% YoY
|
25.28B
25.27B – 25.29B
+8.2% YoY
|
27.79B
27.36B – 28.66B
+9.9% YoY
|
30.59B
30.12B – 31.55B
+10.1% YoY
|
| EBITDA |
509.00M
est: 233.40M (+118.1%)
|
620.00M
est: -64.88M (+1,055.6%)
|
903.00M
est: 653.88M (+38.1%)
|
856.00M
est: 680.60M (+25.8%)
|
614.00M
est: 34.33M (+1,688.3%)
|
856.00M
est: 501.49M (+70.7%)
|
930.00M
est: 608.93M (+52.7%)
|
1.83B
est: 1.47B (+24.3%)
|
1.30B
est: 885.43M (+46.3%)
|
-2.32B
est: -2.52B (+8.0%)
|
940.00M
est: -220.43M (+526.4%)
|
-699.00M
est: -2.29B (+69.5%)
|
-108.00M
est: -894.29M (+87.9%)
|
149.00M
est: -319.10M (+146.7%)
|
1.64B
est: 897.60M (+82.2%)
|
-3.16B
est: -3.57B (+11.4%)
|
721.00M
est: 55.44M (+1,200.4%)
|
433.00M
est: -309.85M (+239.7%)
|
360.00M
est: -353.45M (+201.9%)
|
1.23B
est: 358.10M (+242.4%)
|
2.01B
est: 1.17B (+71.9%)
|
2.59B
est: 1.60B (+61.2%)
|
2.21B
est: 1.16B (+91.2%)
|
1.51B
est: 2.12B (-28.8%)
|
2.52B
est: 2.31B (+9.1%)
|
2.74B
est: 2.65B (+3.3%)
|
3.45B
est: 3.32B (+3.9%)
|
3.94B
est: 3.63B (+8.6%)
|
3.73B
est: 4.38B (-14.8%)
|
4.72B
4.69B – 4.78B
+7.8% YoY
|
5.10B
4.99B – 5.33B
+8.0% YoY
|
5.52B
5.52B – 5.52B
+8.2% YoY
|
6.07B
5.97B – 6.26B
+9.9% YoY
|
6.68B
6.58B – 6.89B
+10.1% YoY
|
| EBIT |
422.00M
est: 409.80M (+3.0%)
|
491.00M
est: -224.20M (+319.0%)
|
725.00M
est: 627.49M (+15.5%)
|
675.00M
est: 650.56M (+3.8%)
|
382.00M
est: 88.67M (+330.8%)
|
695.00M
est: 557.22M (+24.7%)
|
734.00M
est: 660.04M (+11.2%)
|
1.56B
est: 1.55B (+0.3%)
|
981.00M
est: 963.80M (+1.8%)
|
-3.10B
est: -2.00B (-55.1%)
|
1.00M
est: 237.14M (-99.6%)
|
-1.56B
est: -1.85B (+15.3%)
|
-942.00M
est: -886.71M (-6.2%)
|
-667.00M
est: -305.90M (-118.0%)
|
918.00M
est: 865.55M (+6.1%)
|
-3.84B
est: -3.59B (-7.1%)
|
32.00M
est: 70.89M (-54.9%)
|
-292.00M
est: -314.63M (+7.2%)
|
-409.00M
est: -313.59M (-30.4%)
|
411.00M
est: 393.34M (+4.5%)
|
1.16B
est: 1.29B (-9.8%)
|
1.69B
est: 1.45B (+16.4%)
|
1.20B
est: 1.50B (-20.2%)
|
389.00M
est: 1.21B (-67.9%)
|
1.43B
est: 1.09B (+30.4%)
|
1.61B
est: 1.58B (+1.3%)
|
2.26B
est: 2.29B (-1.2%)
|
2.67B
est: 2.49B (+7.1%)
|
3.73B
est: 3.01B (+23.9%)
|
3.25B
3.22B – 3.28B
+7.8% YoY
|
3.51B
3.43B – 3.66B
+8.0% YoY
|
3.79B
3.79B – 3.79B
+8.2% YoY
|
4.17B
4.10B – 4.30B
+9.9% YoY
|
4.59B
4.52B – 4.73B
+10.1% YoY
|
| Net Income |
139.30M
est: 136.50M (+2.1%)
|
-264.40M
est: -168.60M (-56.8%)
|
371.00M
est: 322.62M (+15.0%)
|
373.00M
est: 356.35M (+4.7%)
|
-54.00M
est: -60.44M (+10.7%)
|
373.00M
est: 340.89M (+9.4%)
|
472.00M
est: 445.72M (+5.9%)
|
1.06B
est: 1.05B (+1.3%)
|
628.00M
est: 623.73M (+0.7%)
|
-3.58B
est: -2.54B (-40.7%)
|
-495.00M
est: -185.78M (-166.4%)
|
-2.04B
est: -2.23B (+8.5%)
|
-1.03B
est: -1.04B (+1.3%)
|
-1.07B
est: -686.15M (-55.2%)
|
441.00M
est: 355.90M (+23.9%)
|
-4.07B
est: -3.78B (-7.5%)
|
-121.00M
est: -124.44M (+2.8%)
|
-119.00M
est: -134.20M (+11.3%)
|
-239.00M
est: -229.57M (-4.1%)
|
347.00M
est: 309.06M (+12.3%)
|
104.00M
est: 108.96M (-4.5%)
|
1.67B
est: 1.61B (+3.7%)
|
4.70B
est: 4.52B (+3.9%)
|
-82.00M
est: 1.55B (-105.3%)
|
1.04B
est: 947.28M (+9.8%)
|
698.00M
est: 909.12M (-23.2%)
|
1.59B
est: 1.83B (-12.9%)
|
1.85B
est: 3.68B (-49.7%)
|
2.89B
est: 4.62B (-37.5%)
|
5.04B
4.97B – 5.11B
+9.2% YoY
|
5.58B
5.47B – 5.69B
+10.8% YoY
|
6.27B
5.57B – 6.97B
+12.4% YoY
|
7.03B
6.89B – 7.31B
+12.0% YoY
|
7.76B
7.61B – 8.08B
+10.5% YoY
|
| SGA |
710.40M
est: 696.90M (+1.9%)
|
786.30M
est: 728.02M (+8.0%)
|
842.00M
est: 724.21M (+16.3%)
|
867.00M
est: 841.61M (+3.0%)
|
961.00M
est: 935.22M (+2.8%)
|
1.00B
est: 915.17M (+9.5%)
|
1.17B
est: 1.11B (+5.6%)
|
1.74B
est: 1.71B (+1.7%)
|
1.81B
est: 1.85B (-1.7%)
|
2.61B
est: 2.57B (+1.5%)
|
2.91B
est: 2.49B (+16.8%)
|
2.56B
est: 2.77B (-7.5%)
|
2.62B
est: 4.99B (-47.4%)
|
2.58B
est: 2.59B (-0.4%)
|
2.48B
est: 2.41B (+3.2%)
|
2.52B
est: 2.43B (+3.5%)
|
2.65B
est: 2.31B (+14.7%)
|
2.88B
est: 2.75B (+4.7%)
|
2.85B
est: 2.78B (+2.5%)
|
3.08B
est: 2.95B (+4.5%)
|
3.28B
est: 3.30B (-0.4%)
|
3.56B
est: 3.44B (+3.4%)
|
3.93B
est: 3.86B (+1.7%)
|
3.79B
est: 3.65B (+3.7%)
|
4.29B
est: 4.02B (+6.7%)
|
4.52B
est: 4.55B (-0.7%)
|
5.19B
est: 5.43B (-4.4%)
|
5.98B
est: 5.92B (+1.1%)
|
6.89B
est: 7.15B (-3.7%)
|
7.71B
7.65B – 7.80B
+7.8% YoY
|
8.33B
8.14B – 8.70B
+8.0% YoY
|
9.01B
9.01B – 9.01B
+8.2% YoY
|
9.90B
9.75B – 10.21B
+9.9% YoY
|
10.90B
10.73B – 11.24B
+10.1% YoY
|
| EPS |
0.18
est: 0.42 (-57.1%)
|
-0.34
est: 0.34 (-200.0%)
|
0.46
est: 0.41 (+12.2%)
|
0.46
est: 0.50 (-8.0%)
|
-0.07
est: 0.39 (-116.7%)
|
0.46
est: 0.43 (+7.0%)
|
0.57
est: 0.56 (+1.8%)
|
1.27
est: 1.59 (-20.1%)
|
0.76
est: 1.88 (-59.6%)
|
-2.81
est: 0.80 (-451.3%)
|
-0.33
est: 0.30 (-211.9%)
|
-1.36
est: 0.41 (-435.8%)
|
-0.68
est: 0.54 (-225.9%)
|
-0.70
est: 0.24 (-391.7%)
|
0.29
est: 0.24 (+23.4%)
|
-2.89
est: 0.39 (-841.0%)
|
-0.09
est: 0.35 (-125.7%)
|
-0.09
est: 0.75 (-112.0%)
|
-0.18
est: 0.92 (-119.6%)
|
0.26
est: 1.11 (-76.5%)
|
0.08
est: 1.26 (-93.6%)
|
1.21
est: 1.39 (-13.0%)
|
3.38
est: 1.57 (+115.5%)
|
-0.08
est: 1.04 (-107.8%)
|
0.69
est: 1.61 (-57.1%)
|
0.45
est: 1.73 (-74.1%)
|
1.08
est: 1.25 (-13.3%)
|
1.26
est: 2.47 (-48.9%)
|
1.96
est: 3.04 (-35.4%)
|
3.37
3.33 – 3.42
+10.9% YoY
|
3.73
3.66 – 3.81
+10.8% YoY
|
4.15
3.73 – 4.67
+11.4% YoY
|
4.70
4.61 – 4.89
+13.2% YoY
|
5.20
5.09 – 5.41
+10.5% YoY
|
Recent Grade Changes (3M)
| Date | Firm | Previous | New Grade | Action |
|---|---|---|---|---|
| 2026-06-04 | Truist Securities | Buy | Buy | Maintain |
| 2026-06-03 | BTIG | Buy | Buy | Maintain |
| 2026-06-01 | Canaccord Genuity | Buy | Buy | Maintain |
| 2026-05-29 | Wolfe Research | Outperform | Peer Perform | Downgrade |
| 2026-05-28 | Wells Fargo | Overweight | Equal Weight | Downgrade |
| 2026-05-19 | Baird | Outperform | Outperform | Maintain |
| 2026-05-18 | BTIG | Buy | Buy | Maintain |
| 2026-04-23 | Barclays | Overweight | Overweight | Maintain |
| 2026-04-22 | Barclays | Overweight | Overweight | Maintain |
| 2026-04-21 | Stifel | Buy | Buy | Maintain |
| 2026-04-15 | Truist Securities | Buy | Buy | Maintain |
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-06-12 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-06-11 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-06-10 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-06-09 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-06-08 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-06-05 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-06-04 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-06-03 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-06-02 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-06-01 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-05-28 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-05-27 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-05-26 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-05-22 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-05-21 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-05-20 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-05-19 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-05-18 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-05-15 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-05-14 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-05-13 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-05-12 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-05-11 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-05-08 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-05-07 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-05-06 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-05-05 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-05-04 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-01 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-30 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-29 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-28 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-27 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-24 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-23 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-22 | B | 3/5 | 4/5 | 4/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-21 | B | 3/5 | 4/5 | 4/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-20 | B | 3/5 | 4/5 | 4/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-17 | B | 3/5 | 4/5 | 4/5 | 5/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-16 | B | 3/5 | 4/5 | 4/5 | 5/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-15 | B | 3/5 | 4/5 | 4/5 | 5/5 | 1/5 | 1/5 | 2/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
4.14B
OE per share TTM
2.77
Owner's Yield
5.95%
Maintenance CapEx ratio
4.00%
Maint CapEx / Avg PPE
22.9%
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
1,740
Total invested
84.17B
Insider transactions (90d)
0
Beneficial owners (>5%)
12
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | (1) BlackRock, Inc. | 127.92M | 9.00% | 113.56M | — | 127.92M | — | HC | Delaware | 2022-02-08 | ↗ |
| 2 | The Vanguard Group - 23-1945930 | 111.62M | 7.83% | — | 2.24M | 105.89M | 5.74M | IA | Pennsylvania | 2022-02-09 | ↗ |
| 3 | Capital World Investors ** | 108.07M | 7.70% | 107.36M | — | 108.07M | — | IA | Delaware | 2020-02-14 | ↗ |
| 4 | Abigail P. Johnson | 100.08M | 7.02% | — | — | 100.08M | — | IN | United States of America | 2022-02-09 | ↗ |
| 5 | FMR LLC | 100.08M | 7.02% | 12.18M | — | 100.08M | — | HC | Delaware | 2022-02-09 | ↗ |
| 6 | Wellington Management Company LLP | 92.66M | 6.89% | — | 22.18M | — | — | IA | Massachusetts | 2016-02-11 | ↗ |
| 7 | Wellington Group Holdings LLP | 74.42M | 5.22% | — | 68.68M | — | — | HC | — | 2022-02-04 | ↗ |
| 8 | Wellington Investment Advisors Holdings LLP | 74.42M | 5.22% | — | 68.68M | — | — | HC | — | 2022-02-04 | ↗ |
| 9 | Wellington Management Group LLP | 74.42M | 5.22% | — | 68.68M | — | — | HC | — | 2022-02-04 | ↗ |
| 10 | Boston Scientific Corporation | 544.0K | 8.00% | 544.0K | — | 544.0K | — | CO | — | 2022-02-10 | ↗ |
| 11 | 95-1411037 | 13.00 | 0.50% | 7.28M | — | 7.36M | — | IA | Delaware | 2021-02-16 | ↗ |
| 12 | 04-2747644 | 5.00 | 6.10% | 78.27M | — | 86.64M | — | IA | Delaware | 2022-02-02 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
1,740
-107 vs prev Q
New positions
199
Closed positions
320
Increased
848
Reduced
640
Put/Call ratio
0.37
Calls held
21.97M
Puts held
8.12M
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | VANGUARD GROUP INC | 139.69M +1.4M (+1.0%) | 13.32B -178.2M (-1.3%) | 9.44% +0.085 pp | 0.19% -0.009 pp | USD27.40 +248.0% | 84 qtrs — |
| 2 | BLACKROCK, INC. | 135.99M -9.2M (-6.3%) | 12.97B -1.2B (-8.5%) | 9.19% -0.633 pp | 0.22% -0.029 pp | USD85.30 +11.8% | 6 qtrs — |
| 3 | FMR LLC | 97.39M -2.1M (-2.1%) | 9.29B -426.2M (-4.4%) | 6.57% -0.160 pp | 0.47% -0.032 pp | USD37.47 +154.5% | 70 qtrs — |
| 4 | STATE STREET CORP | 65.85M +920.5K (+1.4%) | 6.28B -60.3M (-1.0%) | 4.45% +0.057 pp | 0.21% -0.009 pp | USD25.04 +280.8% | 51 qtrs — |
| 5 | GEODE CAPITAL MANAGEMENT, LLC | 32.38M -306.8K (-0.9%) | 3.07B -103.5M (-3.3%) | 2.19% -0.024 pp | 0.19% -0.013 pp | USD38.16 +149.9% | 78 qtrs — |
| 6 | PRIMECAP MANAGEMENT CO/CA/ | 31.10M -2.0M (-6.1%) | 2.97B -266.7M (-8.3%) | 2.10% -0.142 pp | 2.24% -0.231 pp | USD17.30 +451.2% | 80 qtrs — |
| 7 | CAPITAL WORLD INVESTORS | 27.15M +502.6K (+1.9%) | 2.59B -12.7M (-0.5%) | 1.83% +0.029 pp | 0.35% -0.003 pp | USD72.01 +32.4% | 10 qtrs — |
| 8 | JPMORGAN CHASE & CO | 25.37M -3.0M (-10.4%) | 2.42B -346.5M (-12.5%) | 1.71% -0.202 pp | 0.15% -0.014 pp | USD52.73 +80.8% | 51 qtrs — |
| 9 | BANK OF AMERICA CORP /DE/ | 25.12M -8.8M (-25.8%) | 2.39B -911.9M (-27.6%) | 1.70% -0.594 pp | 0.17% -0.050 pp | USD56.16 +69.8% | 52 qtrs — |
| 10 | NORGES BANK | 23.07M +23.1M (+100.0%) | 2.20B +2.2B (+100.0%) | 1.56% +1.556 pp | 0.24% +0.235 pp | USD95.35 +0.0% | 1 qtrs NEW |
| 11 | MORGAN STANLEY | 22.96M +2.2M (+10.8%) | 2.19B +167.0M (+8.3%) | 1.55% +0.150 pp | 0.13% +0.008 pp | USD55.19 +72.8% | 51 qtrs — |
| 12 | BOLLARD GROUP LLC | 19.00M -733.1K (-3.7%) | 1.81B -114.9M (-6.0%) | 1.28% -0.053 pp | 45.28% 0.000 pp | USD13.27 +618.5% | 57 qtrs — |
| 13 | DZ BANK AG DEUTSCHE ZENTRAL GENOSSENSCHAFTS BANK, FRANKFURT AM MAIN | 18.54M +4.5M (+32.1%) | 1.77B +397.9M (+29.0%) | 1.25% +0.301 pp | 1.53% +0.327 pp | USD57.16 +66.8% | 37 qtrs — |
| 14 | GOLDMAN SACHS GROUP INC | 16.58M +1.6M (+10.5%) | 1.58B +115.8M (+7.9%) | 1.12% +0.105 pp | 0.19% +0.015 pp | USD49.05 +94.4% | 73 qtrs — |
| 15 | UBS GROUP AG | 14.87M +4.3M (+40.7%) | 1.42B +386.4M (+37.5%) | 1.00% +0.290 pp | 0.23% +0.068 pp | USD74.17 +28.6% | 45 qtrs — |
| 16 | NORTHERN TRUST CORP | 13.94M -467.2K (-3.2%) | 1.33B -77.4M (-5.5%) | 0.94% -0.034 pp | 0.17% -0.011 pp | USD26.79 +255.9% | 51 qtrs — |
| 17 | INVESCO LTD. | 13.32M -3.6M (-21.5%) | 1.27B -386.2M (-23.3%) | 0.90% -0.248 pp | 0.19% -0.066 pp | USD56.84 +67.8% | 57 qtrs — |
| 18 | JANUS HENDERSON GROUP PLC | 12.59M +617.5K (+5.2%) | 1.20B +31.6M (+2.7%) | 0.85% +0.039 pp | 0.54% +0.004 pp | USD34.08 +179.8% | 87 qtrs — |
| 19 | AMUNDI | 12.42M +433.6K (+3.6%) | 1.18B +25.2M (+2.2%) | 0.84% +0.027 pp | 0.32% -0.051 pp | USD61.65 +54.7% | 19 qtrs — |
| 20 | D. E. SHAW & CO., INC. | 11.25M +2.3M (+26.2%) | 1.07B +202.7M (+23.3%) | 0.76% +0.156 pp | 0.59% +0.097 pp | USD98.90 -3.6% | 102 qtrs — |
| 21 | BANK OF NEW YORK MELLON CORP | 11.22M +191.8K (+1.7%) | 1.07B -6.9M (-0.6%) | 0.76% +0.011 pp | 0.19% -0.019 pp | USD29.02 +228.6% | 66 qtrs — |
| 22 | ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | 11.04M +2.7M (+31.9%) | 1.05B +235.3M (+28.8%) | 0.74% +0.178 pp | 0.62% +0.101 pp | USD73.42 +29.9% | 24 qtrs — |
| 23 | UBS ASSET MANAGEMENT AMERICAS INC | 10.94M -41.4K (-0.4%) | 1.04B -29.0M (-2.7%) | 0.74% -0.004 pp | 0.22% -0.012 pp | USD59.60 +60.0% | 90 qtrs — |
| 24 | LEGAL & GENERAL GROUP PLC | 10.88M +419.4K (+4.0%) | 1.04B +16.2M (+1.6%) | 0.73% +0.026 pp | 0.23% +0.001 pp | USD35.20 +170.9% | 75 qtrs — |
| 25 | MILLENNIUM MANAGEMENT LLC | 11.26M +2.7M (+32.1%) | 1.03B +243.0M (+31.0%) | 0.76% +0.184 pp | 0.43% +0.097 pp | USD78.67 +21.2% | 75 qtrs — |
| 26 | WELLINGTON MANAGEMENT GROUP LLP | 9.71M -4.9M (-33.7%) | 925.76M -504.9M (-35.3%) | 0.65% -0.336 pp | 0.16% -0.088 pp | USD35.99 +164.9% | 69 qtrs — |
| 27 | NUVEEN, LLC | 9.37M -273.9K (-2.8%) | 893.65M -48.1M (-5.1%) | 0.63% -0.019 pp | 0.23% -0.015 pp | USD102.48 -7.0% | 4 qtrs — |
| 28 | FISHER ASSET MANAGEMENT, LLC | 9.14M +677.2K (+8.0%) | 871.33M +45.3M (+5.5%) | 0.62% +0.044 pp | 0.30% -0.002 pp | USD69.85 +36.5% | 29 qtrs — |
| 29 | MASSACHUSETTS FINANCIAL SERVICES CO /MA/ | 9.09M -1.3M (-12.4%) | 866.31M -145.9M (-14.4%) | 0.61% -0.088 pp | 0.28% -0.034 pp | USD36.92 +158.3% | 30 qtrs — |
| 30 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 8.95M +104.2K (+1.2%) | 853.05M -10.2M (-1.2%) | 0.60% +0.005 pp | 0.13% -0.005 pp | USD35.21 +170.8% | 100 qtrs — |
| 31 | SCHRODER INVESTMENT MANAGEMENT GROUP | 8.35M +538.7K (+6.9%) | 796.14M +33.6M (+4.4%) | 0.56% +0.035 pp | 0.61% +0.014 pp | USD72.76 +31.0% | 51 qtrs — |
| 32 | PARNASSUS INVESTMENTS, LLC | 7.90M +1.0M (+14.7%) | 753.19M +81.1M (+12.1%) | 0.53% +0.067 pp | 1.95% +0.400 pp | USD97.27 -2.0% | 20 qtrs — |
| 33 | EDGEWOOD MANAGEMENT LLC | 7.80M -1.5M (-16.1%) | 744.04M -164.0M (-18.1%) | 0.53% -0.102 pp | 3.54% +0.325 pp | USD104.94 -9.1% | 3 qtrs — |
| 34 | BNP PARIBAS ASSET MANAGEMENT HOLDING S.A. | 7.72M +3.3M (+74.3%) | 736.43M +304.3M (+70.4%) | 0.52% +0.221 pp | 0.84% -0.275 pp | USD69.44 +37.3% | 51 qtrs — |
| 35 | PRICE T ROWE ASSOCIATES INC /MD/ | 7.46M -920.0K (-11.0%) | 711.05M -106.8M (-13.1%) | 0.50% -0.064 pp | 0.08% -0.011 pp | USD64.83 +47.1% | 75 qtrs — |
| 36 | FARALLON CAPITAL MANAGEMENT LLC | 7.44M +2.7M (+56.7%) | 709.36M +246.0M (+53.1%) | 0.50% +0.181 pp | 3.35% +1.450 pp | USD73.80 +29.2% | 22 qtrs — |
| 37 | CAPITAL RESEARCH GLOBAL INVESTORS | 7.08M +450.3K (+6.8%) | 675.47M +27.8M (+4.3%) | 0.48% +0.029 pp | 0.12% +0.003 pp | USD84.21 +13.2% | 8 qtrs — |
| 38 | CANADA PENSION PLAN INVESTMENT BOARD | 6.86M +1.6M (+30.4%) | 654.27M +140.7M (+27.4%) | 0.46% +0.107 pp | 0.44% +0.077 pp | USD60.67 +57.2% | 52 qtrs — |
| 39 | DEUTSCHE BANK AG\ | 6.75M -1.2M (-15.0%) | 643.44M -131.6M (-17.0%) | 0.46% -0.081 pp | 0.21% -0.050 pp | USD69.61 +37.0% | 50 qtrs — |
| 40 | AMERIPRISE FINANCIAL INC | 6.43M +939.5K (+17.1%) | 613.19M +76.8M (+14.3%) | 0.43% +0.062 pp | 0.14% +0.015 pp | USD58.22 +63.8% | 55 qtrs — |
| 41 | TWO SIGMA ADVISERS, LP | 6.30M +958.7K (+18.0%) | 600.56M +79.2M (+15.2%) | 0.43% +0.064 pp | 1.17% +0.124 pp | USD98.70 -3.4% | 7 qtrs — |
| 42 | DIMENSIONAL FUND ADVISORS LP | 5.74M +1.4M (+32.9%) | 546.89M +125.7M (+29.8%) | 0.39% +0.096 pp | 0.11% +0.024 pp | USD51.45 +85.3% | 51 qtrs — |
| 43 | FRANKLIN RESOURCES INC | 5.68M -1.2M (-17.5%) | 541.21M -130.1M (-19.4%) | 0.38% -0.082 pp | 0.13% -0.035 pp | USD69.29 +37.6% | 28 qtrs — |
| 44 | ROYAL BANK OF CANADA | 5.55M -2.2M (-28.0%) | 529.34M -223.6M (-29.7%) | 0.38% -0.147 pp | 0.09% -0.037 pp | USD72.52 +31.5% | 51 qtrs — |
| 45 | QUBE RESEARCH & TECHNOLOGIES LTD | 5.51M -1.1M (-16.5%) | 524.99M -118.6M (-18.4%) | 0.37% -0.075 pp | 0.53% -0.132 pp | USD98.52 -3.2% | 13 qtrs — |
| 46 | JENNISON ASSOCIATES LLC | 5.47M +529.5K (+10.7%) | 521.40M +39.2M (+8.1%) | 0.37% +0.035 pp | 0.31% +0.032 pp | USD94.33 +1.1% | 12 qtrs — |
| 47 | NINETY ONE UK LTD | 5.44M +81.0K (+1.5%) | 519.14M -4.5M (-0.9%) | 0.37% +0.004 pp | 1.11% -0.018 pp | USD60.16 +58.5% | 15 qtrs — |
| 48 | EGERTON CAPITAL (UK) LLP | 5.39M +72.6K (+1.4%) | 513.47M -5.2M (-1.0%) | 0.36% +0.004 pp | 5.58% +0.111 pp | USD100.58 -5.2% | 3 qtrs — |
| 49 | CITADEL ADVISORS LLC | 4.78M -4.1M (-46.4%) | 455.36M -414.2M (-47.6%) | 0.32% -0.280 pp | 0.07% -0.064 pp | USD75.35 +26.5% | 52 qtrs — |
| 50 | FIL LTD | 4.76M +99.6K (+2.1%) | 453.68M -1.1M (-0.2%) | 0.32% +0.006 pp | 0.34% -0.018 pp | USD53.80 +77.2% | 35 qtrs — |
| 51 | AMERICAN CENTURY COMPANIES INC | 4.60M +603.1K (+15.1%) | 438.82M +48.4M (+12.4%) | 0.31% +0.040 pp | 0.22% +0.022 pp | USD70.18 +35.9% | 51 qtrs — |
| 52 | HOLOCENE ADVISORS, LP | 4.47M +1.5M (+51.5%) | 426.32M +138.2M (+48.0%) | 0.30% +0.102 pp | 0.90% +0.239 pp | USD86.85 +9.8% | 22 qtrs — |
| 53 | MAN GROUP PLC | 4.39M +548.8K (+14.3%) | 418.85M +43.6M (+11.6%) | 0.30% +0.036 pp | 0.71% +0.059 pp | USD98.87 -3.6% | 32 qtrs — |
| 54 | BARCLAYS PLC | 4.36M +285.5K (+7.0%) | 415.79M +74.3M (+21.8%) | 0.29% +0.019 pp | 0.10% +0.012 pp | USD67.18 +41.9% | 51 qtrs — |
| 55 | ASSENAGON ASSET MANAGEMENT S.A. | 4.31M +1.4M (+47.7%) | 410.59M +126.0M (+44.3%) | 0.29% +0.093 pp | 0.57% +0.176 pp | USD90.31 +5.6% | 37 qtrs — |
| 56 | PICTET ASSET MANAGEMENT HOLDING SA | 4.30M +209.4K (+5.1%) | 410.01M +10.7M (+2.7%) | 0.29% +0.013 pp | 0.40% +0.013 pp | USD69.03 +38.1% | 10 qtrs — |
| 57 | WELLS FARGO & COMPANY/MN | 4.14M -22.2K (-0.5%) | 394.47M -11.6M (-2.9%) | 0.28% -0.002 pp | 0.07% -0.005 pp | USD49.58 +92.3% | 57 qtrs — |
| 58 | SWISS NATIONAL BANK | 4.06M -204.2K (-4.8%) | 387.17M -29.2M (-7.0%) | 0.27% -0.015 pp | 0.23% -0.011 pp | USD31.32 +204.4% | 51 qtrs — |
| 59 | POLEN CAPITAL MANAGEMENT LLC | 4.02M -1.6M (-28.2%) | 383.26M -163.3M (-29.9%) | 0.27% -0.108 pp | 1.64% -0.138 pp | USD97.63 -2.3% | 2 qtrs — |
| 60 | NEUBERGER BERMAN GROUP LLC | 4.01M +21.8K (+0.5%) | 382.38M -7.0M (-1.8%) | 0.27% +0.001 pp | 0.28% +0.000 pp | USD46.42 +105.4% | 51 qtrs — |
| 61 | LAZARD ASSET MANAGEMENT LLC | 3.91M -2.8M (-41.8%) | 372.82M -283.2M (-43.2%) | 0.26% -0.191 pp | 0.63% -0.252 pp | USD42.27 +125.6% | 31 qtrs — |
| 62 | BESSEMER GROUP INC | 3.90M +993.8K (+34.2%) | 371.58M +88.1M (+31.1%) | 0.26% +0.067 pp | 0.57% +0.137 pp | USD104.09 -8.4% | 42 qtrs — |
| 63 | JANE STREET GROUP, LLC | 3.79M +815.0K (+27.4%) | 361.69M +70.9M (+24.4%) | 0.26% +0.055 pp | 0.05% +0.010 pp | USD96.91 -1.6% | 44 qtrs — |
| 64 | VONTOBEL HOLDING LTD. | 3.76M -407.9K (-9.8%) | 358.88M -48.4M (-11.9%) | 0.25% -0.028 pp | 1.13% -0.100 pp | USD74.08 +28.7% | 21 qtrs — |
| 65 | NATIONAL PENSION SERVICE | 3.76M +296.4K (+8.6%) | 358.67M +20.4M (+6.0%) | 0.25% +0.019 pp | 0.27% +0.003 pp | USD49.22 +93.7% | 46 qtrs — |
| 66 | HSBC HOLDINGS PLC | 3.61M +215.2K (+6.3%) | 344.73M +13.1M (+3.9%) | 0.24% +0.014 pp | 0.18% -0.007 pp | USD57.34 +66.3% | 56 qtrs — |
| 67 | RAYMOND JAMES FINANCIAL INC | 3.53M +375.8K (+11.9%) | 336.88M +28.6M (+9.3%) | 0.24% +0.025 pp | 0.10% +0.006 pp | USD92.96 +2.6% | 5 qtrs — |
| 68 | SUMITOMO MITSUI TRUST HOLDINGS, INC. | 3.46M -119.3K (-3.3%) | 329.67M -19.5M (-5.6%) | 0.23% -0.009 pp | 0.19% -0.007 pp | USD26.58 +258.7% | 59 qtrs — |
| 69 | SWEDBANK AB | 3.43M +611.2K (+21.7%) | 327.04M +51.8M (+18.8%) | 0.23% +0.041 pp | 0.32% +0.037 pp | USD80.63 +18.3% | 20 qtrs — |
| 70 | WORLDQUANT MILLENNIUM ADVISORS LLC | 3.39M +1.6M (+86.4%) | 322.95M +145.6M (+82.1%) | 0.23% +0.106 pp | 1.25% +0.487 pp | USD94.71 +0.7% | 6 qtrs — |
| 71 | BNP PARIBAS ARBITRAGE, SNC | 3.29M +579.7K (+21.4%) | 314.14M +49.1M (+18.5%) | 0.22% +0.039 pp | 0.14% +0.001 pp | USD77.14 +23.6% | 51 qtrs — |
| 72 | MITSUBISHI UFJ KOKUSAI ASSET MANAGEMENT CO., LTD. | 3.11M +163.2K (+5.5%) | 294.65M +6.9M (+2.4%) | 0.21% +0.010 pp | 0.20% -0.007 pp | USD66.51 +43.4% | 58 qtrs — |
| 73 | KBC GROUP NV | 3.04M +84.8K (+2.9%) | 290.28M +1.3M (+0.5%) | 0.21% +0.005 pp | 0.66% -0.031 pp | USD63.68 +49.7% | 68 qtrs — |
| 74 | SQUAREPOINT OPS LLC | 3.04M +1.2M (+65.4%) | 289.41M +110.2M (+61.5%) | 0.20% +0.081 pp | 0.31% +0.128 pp | USD95.77 -0.4% | 25 qtrs — |
| 75 | CALIFORNIA PUBLIC EMPLOYEES RETIREMENT SYSTEM | 3.01M -248.0K (-7.6%) | 287.20M -31.1M (-9.8%) | 0.20% -0.017 pp | 0.16% -0.026 pp | USD38.93 +144.9% | 58 qtrs — |
| 76 | ROBECO INSTITUTIONAL ASSET MANAGEMENT B.V. | 2.99M -126.0K (-4.0%) | 285.37M -19.1M (-6.3%) | 0.20% -0.009 pp | 0.41% -0.035 pp | USD84.28 +13.1% | 62 qtrs — |
| 77 | MARSHALL WACE, LLP | 2.96M -6.8M (-69.8%) | 281.97M -674.7M (-70.5%) | 0.20% -0.463 pp | 0.26% -0.714 pp | USD77.98 +22.3% | 46 qtrs — |
| 78 | MAVERICK CAPITAL LTD | 2.94M +2.9M (+100.0%) | 280.73M +280.7M (+100.0%) | 0.20% +0.199 pp | 3.01% +3.014 pp | USD95.35 +0.0% | 1 qtrs NEW |
| 79 | SKANDINAVISKA ENSKILDA BANKEN AB (PUBL) | 2.84M +280.4K (+11.0%) | 270.32M +20.9M (+8.4%) | 0.19% +0.019 pp | 1.08% +0.083 pp | USD82.37 +15.8% | 41 qtrs — |
| 80 | ALLIANCEBERNSTEIN L.P. | 2.80M -185.7K (-6.2%) | 267.05M -24.5M (-8.4%) | 0.19% -0.013 pp | 0.08% -0.008 pp | USD64.72 +47.3% | 61 qtrs — |
| 81 | RATHBONES GROUP PLC | 2.76M +477.7K (+20.9%) | 263.13M +40.3M (+18.1%) | 0.19% +0.032 pp | 1.04% +0.137 pp | USD54.64 +74.5% | 14 qtrs — |
| 82 | ALECTA TJANSTEPENSION OMSESIDIGT | 2.74M +— (+0.0%) | 261.58M -6.2M (-2.3%) | 0.19% -0.001 pp | 1.15% -0.044 pp | USD64.04 +48.9% | 10 qtrs — |
| 83 | RHUMBLINE ADVISERS | 2.70M -28.8K (-1.1%) | 257.21M -9.0M (-3.4%) | 0.18% -0.002 pp | 0.21% -0.006 pp | USD23.69 +302.5% | 51 qtrs — |
| 84 | ALPHINITY INVESTMENT MANAGEMENT PTY LTD | 2.65M +2.7M (+100.0%) | 252.92M +252.9M (+100.0%) | 0.18% +0.179 pp | 2.56% +2.561 pp | USD95.35 +0.0% | 1 qtrs NEW |
| 85 | ABRDN PLC | 2.64M -632.0 (0.0%) | 252.14M -5.5M (-2.1%) | 0.18% -0.001 pp | 0.39% -0.017 pp | USD38.28 +149.1% | 34 qtrs — |
| 86 | ENVESTNET ASSET MANAGEMENT INC | 2.61M -262.5K (-9.1%) | 248.58M -31.6M (-11.3%) | 0.18% -0.018 pp | 0.07% -0.007 pp | USD57.72 +65.2% | 49 qtrs — |
| 87 | ARTISAN PARTNERS LIMITED PARTNERSHIP | 2.57M -2.2M (-46.0%) | 244.99M -219.4M (-47.2%) | 0.17% -0.148 pp | 0.37% -0.292 pp | USD32.09 +197.1% | 43 qtrs — |
| 88 | SURGOCAP PARTNERS LP | 2.56M -865.7K (-25.3%) | 244.02M -90.4M (-27.0%) | 0.17% -0.059 pp | 6.76% -2.540 pp | USD100.36 -5.0% | 4 qtrs — |
| 89 | HANDELSBANKEN FONDER AB | 2.52M +263.7K (+11.7%) | 240.29M +20.0M (+9.1%) | 0.17% +0.018 pp | 0.73% +0.026 pp | USD73.67 +29.4% | 23 qtrs — |
| 90 | VIKING GLOBAL INVESTORS LP | 2.51M -131.9K (-5.0%) | 239.31M -18.6M (-7.2%) | 0.17% -0.009 pp | 0.64% -0.035 pp | USD92.32 +3.3% | 30 qtrs — |
| 91 | BALYASNY ASSET MANAGEMENT L.P. | 2.48M +927.8K (+59.7%) | 236.63M +84.9M (+56.0%) | 0.17% +0.062 pp | 0.30% +0.108 pp | USD80.60 +18.3% | 19 qtrs — |
| 92 | TWO SIGMA INVESTMENTS, LP | 2.47M -60.2K (-2.4%) | 235.64M -11.5M (-4.7%) | 0.17% -0.004 pp | 0.33% -0.036 pp | USD93.24 +2.3% | 25 qtrs — |
| 93 | POINT72 ASSET MANAGEMENT, L.P. | 2.43M +803.5K (+49.3%) | 232.14M +72.9M (+45.8%) | 0.16% +0.054 pp | 0.26% -0.007 pp | USD79.16 +20.5% | 18 qtrs — |
| 94 | ORBIMED ADVISORS LLC | 2.42M -10.0K (-0.4%) | 230.68M -6.5M (-2.7%) | 0.16% -0.001 pp | 4.73% -0.862 pp | USD26.13 +264.9% | 68 qtrs — |
| 95 | RENAISSANCE TECHNOLOGIES LLC | 2.38M +1.5M (+159.8%) | 227.19M +137.7M (+153.7%) | 0.16% +0.099 pp | 0.35% +0.234 pp | USD98.90 -3.6% | 6 qtrs — |
| 96 | CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | 2.36M -47.0K (-2.0%) | 224.81M -10.0M (-4.2%) | 0.16% -0.004 pp | 0.22% -0.016 pp | USD21.11 +351.7% | 52 qtrs — |
| 97 | NATIXIS ADVISORS, L.P. | 2.21M -298.1K (-11.9%) | 210.59M -34.1M (-14.0%) | 0.15% -0.021 pp | 0.30% -0.059 pp | USD62.25 +53.2% | 57 qtrs — |
| 98 | SEI INVESTMENTS CO | 2.21M -87.1K (-3.8%) | 210.47M -13.5M (-6.0%) | 0.15% -0.006 pp | 0.21% -0.033 pp | USD35.54 +168.3% | 45 qtrs — |
| 99 | 1832 ASSET MANAGEMENT L.P. | 2.20M +2.2M (+6,401.5%) | 209.93M +206.6M (+6,249.6%) | 0.15% +0.146 pp | 0.16% +0.157 pp | USD94.68 +0.7% | 24 qtrs — |
| 100 | UNISPHERE ESTABLISHMENT | 2.18M +69.5K (+3.3%) | 207.55M +1.8M (+0.9%) | 0.15% +0.004 pp | 1.55% -0.061 pp | USD64.96 +46.8% | 9 qtrs — |
Ownership breakdown by holder
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
5.00
Bullish
Ratio by volume
3.00
Bullish
Buys
20
Sells
4
Shares acquired
54.4K
Shares disposed
5.8K
Cash buys
4.00
Cash sales
—
Net activity
+48,659
Insider buys vs sells (history)
From
To
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
EBIT / Employee
70.4K
Shares Outstanding
1.49B
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2025 | Michael F. Mahoney Chairman of the Board, President and Chief Executive Officer | 1.44M | — | 13.61M | 3.75M | 4.00M | 729.4K | 23.53M | 73.76% | ↗ |
| 2 | 2025 | Joseph M. Fitzgerald Executive Vice President and Group President, Cardiovascular | 892.6K | — | 4.31M | 1.19M | 1.46M | 195.6K | 8.04M | 68.34% | ↗ |
| 3 | 2025 | Arthur C. Butcher Executive Vice President and Group President, MedSurg and Asia Pacific | 744.8K | — | 3.45M | 950.0K | 1.01M | 380.2K | 6.53M | 67.29% | ↗ |
| 4 | 2025 | Daniel J. Brennan Former Executive Vice President and Chief Financial Officer | 661.0K | — | 3.45M | 950.0K | 1.10M | 126.7K | 6.28M | 69.99% | ↗ |
| 5 | 2025 | Jonathan R. Monson Executive Vice President and Chief Financial Officer | 591.8K | — | 1.62M | 1.17M | 840.0K | 1.86M | 6.08M | 45.95% | ↗ |
| 6 | 2025 | Jeffrey B. Mirviss Executive Vice President and President, Peripheral Interventions | 702.0K | — | 2.00M | 550.0K | 793.1K | 119.2K | 4.16M | 61.19% | ↗ |
| 7 | 2025 | Vance R. Brown Senior Vice President, General Counsel and Corporate Secretary | 659.1K | — | 1.72M | 475.0K | 897.8K | 165.2K | 3.92M | 56.08% | ↗ |
| 8 | 2024 | Michael F. Mahoney Chairman of the Board, President and Chief Executive Officer | 1.40M | — | 12.23M | 3.56M | 3.74M | 485.1K | 21.42M | 73.73% | ↗ |
| 9 | 2024 | Daniel J. Brennan Executive Vice President and Chief Financial Officer | 843.1K | — | 3.26M | 950.0K | 1.47M | 160.0K | 6.69M | 62.98% | ↗ |
| 10 | 2024 | Daniel J. Brennan Former Executive Vice President and Chief Financial Officer | 843.1K | — | 3.26M | 950.0K | 1.47M | 160.0K | 6.69M | 62.98% | ↗ |
| 11 | 2024 | Joseph M. Fitzgerald Executive Vice President and Group President, Cardiovascular | 842.4K | — | 3.09M | 900.0K | 1.32M | 184.2K | 6.34M | 62.97% | ↗ |
| 12 | 2024 | Joseph M. Fitzgerald Executive Vice President and Group President, Cardiology | 842.4K | — | 3.09M | 900.0K | 1.32M | 184.2K | 6.34M | 62.97% | ↗ |
| 13 | 2024 | Arthur C. Butcher Executive Vice President and Group President, MedSurg and Asia Pacific | 708.9K | — | 2.40M | 700.0K | 957.2K | 244.5K | 5.01M | 61.89% | ↗ |
| 14 | 2024 | Jeffrey B. Mirviss Executive Vice President and President, Peripheral Interventions | 680.4K | — | 1.89M | 550.0K | 770.6K | 138.1K | 4.03M | 60.54% | ↗ |
| 15 | 2023 | Michael F. Mahoney Chairman of the Board, President and Chief Executive Officer | 1.40M | — | 10.47M | 3.12M | 3.24M | 481.8K | 18.72M | 72.62% | ↗ |
| 16 | 2023 | Daniel J. Brennan Former Executive Vice President and Chief Financial Officer | 801.5K | — | 2.76M | 825.0K | 1.32M | 113.9K | 5.83M | 61.58% | ↗ |
| 17 | 2023 | Daniel J. Brennan Executive Vice President and Chief Financial Officer | 801.5K | — | 2.76M | 825.0K | 1.32M | 113.9K | 5.83M | 61.58% | ↗ |
| 18 | 2023 | Joseph M. Fitzgerald Executive Vice President and Group President, Cardiovascular | 793.6K | — | 2.76M | 825.0K | 1.02M | 192.5K | 5.59M | 64.19% | ↗ |
| 19 | 2023 | Joseph M. Fitzgerald Executive Vice President and Group President, Cardiology | 793.6K | — | 2.76M | 825.0K | 1.02M | 192.5K | 5.59M | 64.19% | ↗ |
| 20 | 2023 | Arthur C. Butcher Executive Vice President and Group President, MedSurg and Asia Pacific | 672.1K | — | 2.01M | 600.0K | 756.9K | 216.5K | 4.26M | 61.34% | ↗ |
| 21 | 2023 | Jeffrey B. Mirviss Executive Vice President and President, Peripheral Interventions | 652.6K | — | 1.76M | 525.0K | 734.4K | 111.5K | 3.78M | 60.39% | ↗ |
| 22 | 2022 | Michael F. Mahoney Chairman of the Board, President and Chief Executive Officer | 1.40M | — | 9.92M | 2.87M | 2.28M | 469.2K | 16.94M | 75.55% | ↗ |
| 23 | 2022 | Arthur C. Butcher Executive Vice President and Group President, MedSurg and Asia Pacific | 634.3K | — | 1.90M | 800.0K | 471.1K | 69.3K | 5.96M | 45.38% | ↗ |
| 24 | 2022 | Daniel J. Brennan Executive Vice President and Chief Financial Officer | 766.0K | — | 2.59M | 750.0K | 900.2K | 247.1K | 5.25M | 63.57% | ↗ |
| 25 | 2022 | Joseph M. Fitzgerald Executive Vice President and Group President, Cardiology | 740.2K | — | 2.42M | 700.0K | 764.6K | 143.5K | 4.76M | 65.40% | ↗ |
| 26 | 2022 | Jeffrey B. Mirviss Executive Vice President and President, Peripheral Interventions | 632.0K | — | 1.81M | 525.0K | 482.3K | 110.8K | 3.56M | 65.61% | ↗ |
| 27 | 2021 | Michael F. Mahoney Chairman of the Board, President and Chief Executive Officer | 1.34M | — | 9.13M | 2.75M | 2.35M | 497.4K | 16.06M | 73.93% | ↗ |
| 28 | 2021 | Daniel J. Brennan Executive Vice President and Chief Financial Officer | 692.2K | — | 2.28M | 687.5K | 684.3K | 84.4K | 4.43M | 67.02% | ↗ |
| 29 | 2021 | Joseph M. Fitzgerald Executive Vice President and Group President, Cardiology | 699.1K | — | 2.07M | 625.0K | 843.2K | 68.1K | 4.31M | 62.63% | ↗ |
| 30 | 2021 | Jeffrey B. Mirviss Executive Vice President and President, Peripheral Interventions | 598.2K | — | 1.66M | 500.0K | 573.5K | 125.1K | 3.46M | 62.48% | ↗ |
| 31 | 2020 | Michael F. Mahoney Chairman of the Board, President and Chief Executive Officer | 666.9K | — | 8.40M | 2.75M | 1.49M | 476.6K | 13.77M | 80.92% | ↗ |
| 32 | 2020 | Joseph M. Fitzgerald Executive Vice President and Group President, Cardiology | 568.7K | — | 1.91M | 1.62M | 414.0K | 82.7K | 4.60M | 76.83% | ↗ |
| 33 | 2020 | Joseph M. Fitzgerald Executive Vice President and President, Interventional Cardiology | 568.7K | — | 1.91M | 1.62M | 414.0K | 82.7K | 4.60M | 76.83% | ↗ |
| 34 | 2020 | Daniel J. Brennan Executive Vice President and Chief Financial Officer | 560.4K | — | 1.91M | 625.0K | 455.2K | 120.4K | 3.67M | 69.04% | ↗ |
| 35 | 2020 | Edward F. Mackey Executive Vice President, Operations | 497.7K | — | 2.14M | 375.0K | 391.4K | 190.8K | 3.60M | 70.00% | ↗ |
| 36 | 2020 | Jeffrey B. Mirviss Executive Vice President and President, Peripheral Interventions | 495.0K | — | 1.45M | 475.0K | 350.2K | 186.0K | 2.96M | 65.12% | ↗ |
| 37 | 2019 | Michael F. Mahoney Chairman of the Board, President and Chief Executive Officer | 1.27M | — | 9.09M | 2.70M | 2.00M | 705.4K | 15.76M | 74.77% | ↗ |
| 38 | 2019 | Daniel J. Brennan Executive Vice President and Chief Financial Officer | 655.4K | — | 1.98M | 587.5K | 583.5K | 227.6K | 4.03M | 63.62% | ↗ |
| 39 | 2019 | Joseph M. Fitzgerald Executive Vice President and President, Rhythm Management | 667.4K | — | 2.10M | 625.0K | 546.8K | 82.8K | 4.03M | 67.78% | ↗ |
| 40 | 2019 | Joseph M. Fitzgerald Executive Vice President and President, Interventional Cardiology | 667.4K | — | 2.10M | 625.0K | 546.8K | 82.8K | 4.03M | 67.78% | ↗ |
| 41 | 2019 | Kevin J. Ballinger Executive Vice President and President, Interventional Cardiology | 587.4K | — | 1.60M | 475.0K | 460.2K | 247.4K | 3.37M | 61.56% | ↗ |
| 42 | 2019 | Edward F. Mackey Executive Vice President, Operations | 577.4K | — | 1.47M | 437.5K | 520.3K | 191.4K | 3.20M | 59.70% | ↗ |
| 43 | 2018 | Michael F. Mahoney Chairman of the Board, President and Chief Executive Officer | 1.23M | — | 7.64M | 2.50M | 2.13M | 463.6K | 13.97M | 72.61% | ↗ |
| 44 | 2018 | Joseph M. Fitzgerald Executive Vice President and President, Interventional Cardiology | 640.0K | — | 1.91M | 625.0K | 582.4K | 278.0K | 4.04M | 62.83% | ↗ |
| 45 | 2018 | Joseph M. Fitzgerald Executive Vice President and President, Rhythm Management | 640.0K | — | 1.91M | 625.0K | 582.4K | 278.0K | 4.04M | 62.83% | ↗ |
| 46 | 2018 | Daniel J. Brennan Executive Vice President and Chief Financial Officer | 621.6K | — | 1.72M | 562.5K | 626.7K | 135.1K | 3.67M | 62.26% | ↗ |
| 47 | 2018 | Kevin J. Ballinger Executive Vice President and President, Interventional Cardiology | 567.4K | — | 1.34M | 437.5K | 448.9K | 50.1K | 2.84M | 62.47% | ↗ |
| 48 | 2018 | David A. Pierce Executive Vice President and President, MedSurg | 539.0K | — | 1.15M | 375.0K | 500.2K | 170.7K | 2.73M | 55.70% | ↗ |
| 49 | 2017 | Michael F. Mahoney Chairman of the Board, President and Chief Executive Officer | 1.18M | — | 7.23M | 2.25M | 1.89M | 539.4K | 13.08M | 72.42% | ↗ |
| 50 | 2017 | Joseph M. Fitzgerald Executive Vice President and President, Rhythm Management | 564.7K | — | 1.44M | 2.95M | 595.1K | 293.4K | 5.84M | 75.11% | ↗ |
| 51 | 2017 | Daniel J. Brennan Executive Vice President and Chief Financial Officer | 593.2K | — | 1.77M | 550.0K | 504.0K | 219.3K | 3.63M | 63.76% | ↗ |
| 52 | 2017 | Kevin J. Ballinger Executive Vice President and President, Interventional Cardiology | 543.2K | — | 1.32M | 412.5K | 346.5K | 190.3K | 2.81M | 61.55% | ↗ |
| 53 | 2017 | Timothy A. Pratt Former Executive Vice President, Chief Administrative Officer, General Counsel and Secretary | 653.0K | — | 963.3K | 300.0K | 550.2K | 192.3K | 2.66M | 47.51% | ↗ |
| 54 | 2016 | Michael F. Mahoney Chairman of the Board, President and Chief Executive Officer | 1.04M | — | 6.25M | 2.00M | 2.35M | 383.8K | 12.03M | 68.56% | ↗ |
| 55 | 2016 | Daniel J. Brennan Executive Vice President and Chief Financial Officer | 544.4K | — | 1.56M | 499.7K | 500.5K | 208.7K | 3.32M | 62.18% | ↗ |
| 56 | 2016 | Timothy A. Pratt Executive Vice President, Chief Administrative Officer, General Counsel and Secretary | 640.0K | — | 937.0K | 299.8K | 665.6K | 157.9K | 2.70M | 45.80% | ↗ |
| 57 | 2016 | Timothy A. Pratt Former Executive Vice President, Chief Administrative Officer, General Counsel and Secretary | 640.0K | — | 937.0K | 299.8K | 665.6K | 157.9K | 2.70M | 45.80% | ↗ |
| 58 | 2016 | Kevin J. Ballinger Executive Vice President and President, Interventional Cardiology | 476.6K | — | 1.02M | 324.8K | 483.0K | 236.9K | 2.54M | 52.83% | ↗ |
| 59 | 2016 | Joseph M. Fitzgerald Executive Vice President and President, Rhythm Management | 499.2K | — | 1.09M | 349.8K | 367.5K | 117.9K | 2.43M | 59.44% | ↗ |
| 60 | 2015 | Michael F. Mahoney Chairman of the Board, President and Chief Executive Officer | 967.7K | — | 6.59M | 1.94M | 1.83M | 276.4K | 11.59M | 73.53% | ↗ |
| 61 | 2015 | Michael F. Mahoney President and Chief Executive Officer | 967.7K | — | 6.59M | 1.94M | 1.83M | 276.4K | 11.59M | 73.53% | ↗ |
| 62 | 2015 | Edward F. Mackey Executive Vice President, Operations | 410.5K | — | 2.28M | 597.6K | 351.0K | 181.5K | 3.82M | 75.30% | ↗ |
| 63 | 2015 | Daniel J. Brennan Executive Vice President and Chief Financial Officer | 492.7K | — | 1.49M | 437.6K | 523.3K | 168.9K | 3.11M | 61.90% | ↗ |
| 64 | 2015 | Timothy A. Pratt Executive Vice President, Chief Administrative Officer, General Counsel and Secretary | 638.6K | — | 1.02M | 300.1K | 665.6K | 171.1K | 2.80M | 47.22% | ↗ |
| 65 | 2015 | Timothy A. Pratt Former Executive Vice President, Chief Administrative Officer, General Counsel and Secretary | 638.6K | — | 1.02M | 300.1K | 665.6K | 171.1K | 2.80M | 47.22% | ↗ |
| 66 | 2015 | Joseph M. Fitzgerald Executive Vice President and President, Rhythm Management | 481.4K | — | 1.15M | 337.6K | 424.4K | 121.7K | 2.51M | 59.11% | ↗ |
| 67 | 2015 | Kevin J. Ballinger Executive Vice President and President, Interventional Cardiology | 424.9K | — | 1.02M | 300.1K | 415.4K | 100.7K | 2.26M | 58.38% | ↗ |
| 68 | 2014 | Michael F. Mahoney President and Chief Executive Officer | 921.3K | — | 6.04M | 1.90M | 1.40M | 258.5K | 10.53M | 75.46% | ↗ |
| 69 | 2014 | Michael F. Mahoney Chairman of the Board, President and Chief Executive Officer | 921.3K | — | 6.04M | 1.90M | 1.40M | 258.5K | 10.53M | 75.46% | ↗ |
| 70 | 2014 | Daniel J. Brennan Executive Vice President and Chief Financial Officer | 450.0K | — | 1.19M | 374.9K | 416.6K | 1.12M | 3.56M | 44.06% | ↗ |
| 71 | 2014 | Timothy A. Pratt Executive Vice President, Chief Administrative Officer, General Counsel and Secretary | 627.3K | — | 954.3K | 300.0K | 579.6K | 171.7K | 2.63M | 47.64% | ↗ |
| 72 | 2014 | Joseph M. Fitzgerald Executive Vice President and President, Rhythm Management | 454.1K | — | 994.1K | 312.5K | 425.0K | 206.3K | 2.39M | 54.62% | ↗ |
| 73 | 2014 | Kevin J. Ballinger Executive Vice President and President, Interventional Cardiology | 392.8K | — | 596.4K | 187.5K | 414.8K | 345.9K | 1.94M | 40.46% | ↗ |
| 74 | 2013 | Michael F. Mahoney President and Chief Executive Officer | 900.0K | — | 6.65M | 1.87M | 1.24M | 186.9K | 10.85M | 78.54% | ↗ |
| 75 | 2013 | Jeffrey D. Capello Former Executive Vice President and Chief Financial Officer | 607.6K | — | 1.86M | 525.0K | 561.2K | 16.6K | 3.57M | 66.81% | ↗ |
| 76 | 2013 | Timothy A. Pratt Executive Vice President, Chief Administrative Officer, General Counsel and Secretary | 612.0K | — | 1.11M | 312.5K | 563.0K | 153.1K | 2.75M | 51.68% | ↗ |
| 77 | 2013 | Kenneth J. Pucel Executive Vice President, Global Operations, Quality and Technology | 517.7K | — | 1.24M | 350.0K | 481.4K | 14.4K | 2.60M | 61.08% | ↗ |
| 78 | 2013 | Supratim Bose Executive Vice President and President, AMEA | 537.3K | — | 886.3K | 250.0K | 293.0K | 161.9K | 2.13M | 53.39% | ↗ |
| 79 | 2012 | Michael F. Mahoney President and Chief Executive Officer | 900.0K | 750.0K | 5.87M | 1.73M | 1.03M | 508.2K | 10.78M | 70.47% | ↗ |
| 80 | 2012 | William H. Kucheman Former Chief Executive Officer | 900.0K | — | 2.52M | 721.8K | 1.03M | 1.89M | 7.06M | 45.92% | ↗ |
| 81 | 2012 | Jeffrey D. Capello Executive Vice President and Chief Financial Officer | 593.9K | — | 1.54M | 433.1K | 452.4K | 155.4K | 3.18M | 62.17% | ↗ |
| 82 | 2012 | Jeffrey D. Capello Former Executive Vice President and Chief Financial Officer | 593.9K | — | 1.54M | 433.1K | 452.4K | 155.4K | 3.18M | 62.17% | ↗ |
| 83 | 2012 | Timothy A. Pratt Executive Vice President, Chief Administrative Officer, General Counsel and Secretary | 612.0K | — | 1.05M | 288.7K | 465.1K | 166.1K | 2.58M | 51.90% | ↗ |
| 84 | 2012 | Kenneth J. Pucel Executive Vice President, Global Operations, Quality and Technology | 505.0K | — | 1.05M | 288.7K | 369.4K | 146.2K | 2.36M | 56.80% | ↗ |
| 85 | 2012 | Supratim Bose Executive Vice President and President, Asia-Pacific | 535.8K | — | 726.0K | 496.2K | 366.5K | 207.3K | 2.33M | 52.42% | ↗ |
| 86 | 2012 | Supratim Bose Executive Vice President and President, AMEA | 518.0K | — | 726.0K | 496.2K | 354.3K | 203.7K | 2.30M | 53.18% | ↗ |
| 87 | 2011 | Michael F. Mahoney President | 187.4K | 1.50M | 9.53M | — | 238.1K | 329.0K | 11.79M | 80.87% | ↗ |
| 88 | 2011 | Michael F. Mahoney President and Chief Executive Officer | 187.4K | 1.50M | 9.53M | — | 238.1K | 329.0K | 11.79M | 80.87% | ↗ |
| 89 | 2011 | Samuel R. Leno Former Executive Vice President and Chief Operations Officer | 657.6K | — | 1.65M | 1.75M | 528.0K | 2.60M | 7.18M | 47.33% | ↗ |
| 90 | 2011 | William H. Kucheman Chief Executive Officer | 630.8K | — | 1.27M | 987.6K | 560.0K | 1.24M | 4.69M | 48.06% | ↗ |
| 91 | 2011 | William H. Kucheman Former Chief Executive Officer | 630.8K | — | 1.27M | 987.6K | 560.0K | 1.24M | 4.69M | 48.06% | ↗ |
| 92 | 2011 | Jeffrey D. Capello Former Executive Vice President and Chief Financial Officer | 584.7K | — | 1.20M | 990.7K | 431.1K | 152.6K | 3.36M | 65.21% | ↗ |
| 93 | 2011 | Jeffrey D. Capello Executive Vice President and Chief Financial Officer | 584.7K | — | 1.20M | 990.7K | 431.1K | 152.6K | 3.36M | 65.21% | ↗ |
| 94 | 2011 | Stephen F. Moreci Former Senior Vice President, Global Sales Operations | 448.8K | — | 412.7K | 430.9K | 270.0K | 1.71M | 3.28M | 25.76% | ↗ |
| 95 | 2011 | Timothy A. Pratt Executive Vice President, Chief Administrative Officer, General Counsel and Secretary | 610.1K | — | 949.5K | 740.7K | 514.1K | 187.9K | 3.00M | 56.30% | ↗ |
| 96 | 2011 | Kenneth J. Pucel Executive Vice President, Global Operations, Quality and Technology | 503.8K | — | 949.5K | 740.7K | 375.6K | 210.9K | 2.78M | 60.79% | ↗ |
| 97 | 2011 | J. Raymond Elliott Former President and Chief Executive Officer | 1.13M | — | — | — | 1.13M | 399.2K | 2.66M | 0.00% | ↗ |
| 98 | 2010 | Jeffrey D. Capello Executive Vice President and Chief Financial Officer | 564.5K | — | 1.68M | 2.73M | 381.5K | 146.3K | 5.50M | 80.12% | ↗ |
| 99 | 2010 | J. Raymond Elliott Former President and Chief Executive Officer | 1.20M | — | — | 2.08M | 1.04M | 593.4K | 4.92M | 42.28% | ↗ |
| 100 | 2010 | Samuel R. Leno Former Executive Vice President and Chief Operations Officer | 642.5K | — | 1.50M | 1.03M | 501.3K | 272.3K | 3.95M | 64.12% | ↗ |
| 101 | 2010 | Timothy A. Pratt Executive Vice President, Chief Administrative Officer, General Counsel and Secretary | 590.8K | — | 1.45M | 647.6K | 455.0K | 229.1K | 3.37M | 62.19% | ↗ |
| 102 | 2010 | William H. Kucheman Chief Executive Officer | 489.5K | 50.0K | 1.13M | 1.03M | 180.1K | 303.0K | 3.18M | 67.87% | ↗ |
| 103 | 2010 | William H. Kucheman Former Chief Executive Officer | 489.5K | 50.0K | 1.13M | 1.03M | 180.1K | 303.0K | 3.18M | 67.87% | ↗ |
| 104 | 2010 | Kenneth J. Pucel Executive Vice President, Global Operations, Quality and Technology | 453.2K | 105.1K | 566.5K | 521.1K | 284.7K | 471.0K | 2.40M | 45.29% | ↗ |
| 105 | 2010 | Stephen F. Moreci Former Senior Vice President, Global Sales Operations | 440.6K | — | 424.9K | 394.5K | 253.7K | 114.8K | 1.63M | 50.32% | ↗ |
| 106 | 2009 | J. Raymond Elliott Former President and Chief Executive Officer | 598.4K | 1.50M | 14.16M | 15.23M | 607.8K | 1.37M | 33.47M | 87.82% | ↗ |
| 107 | 2009 | Samuel R. Leno Former Executive Vice President and Chief Operations Officer | 625.0K | — | 250.0K | 750.0K | 420.9K | 223.8K | 2.27M | 44.06% | ↗ |
| 108 | 2009 | Stephen F. Moreci Former Senior Vice President, Global Sales Operations | 427.5K | — | — | 500.0K | 283.8K | 402.1K | 1.61M | 30.99% | ↗ |
| 109 | 2006 | James R. Tobin President and Chief Executive Officer | 922.6K | — | 5.10M | 1.40M | 324.1K | 612.4K | 8.36M | 77.76% | ↗ |
| 110 | 2006 | Fredericus A. Colen Executive Vice President, Operations and Technology, CRM and Chief Technology Officer | 488.3K | — | 960.2K | 1.55M | 469.5K | 307.3K | 3.77M | 66.47% | ↗ |
| 111 | 2006 | Lawrence C. Best Executive Vice President — Finance & Administration and Chief Financial Officer | 660.1K | — | 784.1K | 1.42M | 494.4K | 378.7K | 3.74M | 59.01% | ↗ |
| 112 | 2006 | Paul A. LaViolette Chief Operating Officer | 660.0K | — | 447.6K | 1.43M | 616.4K | 408.1K | 3.56M | 52.73% | ↗ |
| 113 | 2006 | Paul W. Sandman Executive Vice President and General Counsel | 460.0K | 400.0K | 358.2K | 938.7K | 344.6K | 358.1K | 2.86M | 45.35% | ↗ |
| 114 | 2004 | James R. Tobin President and Chief Executive Officer | 875.0K | 974.9K | — | 225.0K | — | 297.4K | 2.37M | 9.48% | ↗ |
| 115 | 2004 | Lawrence C. Best Executive Vice President — Finance & Administration and Chief Financial Officer | 600.3K | 501.1K | — | 60.0K | — | 53.8K | 1.22M | 4.94% | ↗ |
| 116 | 2004 | Paul A. LaViolette Chief Operating Officer | 500.2K | 501.1K | — | 100.0K | — | 70.9K | 1.17M | 8.53% | ↗ |
| 117 | 2004 | Paul W. Sandman Executive Vice President, Secretary and General Counsel | 420.3K | 350.8K | — | 60.0K | — | 111.8K | 942.9K | 6.36% | ↗ |
| 118 | 2004 | Fredericus A. Colen Executive Vice President and Chief Technology Officer | 400.1K | 334.2K | — | 60.0K | — | 88.3K | 882.6K | 6.80% | ↗ |
| 119 | 2003 | James R. Tobin(4,5) President and Chief Executive Officer | 824.4K | 1.10M | — | 400.0K | — | 103.4K | 2.43M | 16.49% | ↗ |
| 120 | 2003 | James R. Tobin President and Chief Executive Officer | 824.4K | 1.10M | — | 200.0K | — | 118.4K | 2.24M | 8.92% | ↗ |
| 121 | 2003 | Lawrence C. Best Executive Vice President — Finance & Administration and Chief Financial Officer | 575.0K | 527.2K | — | 60.0K | — | 36.2K | 1.20M | 5.01% | ↗ |
| 122 | 2003 | Lawrence C. Best Senior Vice President — Finance & Administration and Chief Financial Officer | 575.0K | 527.2K | — | 60.0K | — | 11.2K | 1.17M | 5.11% | ↗ |
| 123 | 2003 | Paul A. LaViolette Chief Operating Officer | 458.0K | 548.3K | — | 75.0K | — | 58.9K | 1.14M | 6.58% | ↗ |
| 124 | 2003 | Paul A. LaViolette Senior Vice President and Group President, Cardiovascular | 458.0K | 548.3K | — | 75.0K | — | 33.9K | 1.12M | 6.73% | ↗ |
| 125 | 2003 | Paul W. Sandman Executive Vice President, Secretary and General Counsel | 395.0K | 346.4K | — | 60.0K | — | 100.0K | 901.5K | 6.66% | ↗ |
| 126 | 2003 | Fredericus A. Colen Executive Vice President and Chief Technology Officer | 375.0K | 373.7K | — | 60.0K | — | 84.0K | 892.8K | 6.72% | ↗ |
| 127 | 2003 | Paul W. Sandman Senior Vice President, Secretary and General Counsel | 395.0K | 346.4K | — | 60.0K | — | 75.0K | 876.5K | 6.85% | ↗ |
| 128 | 2003 | Fredericus A. Colen Senior Vice President and Chief Technology Officer | 375.0K | 373.7K | — | 60.0K | — | 59.0K | 867.8K | 6.91% | ↗ |
| 129 | 2002 | James R. Tobin President and Chief Executive Officer | 795.0K | 795.4K | — | 200.0K | — | 86.0K | 1.88M | 10.66% | ↗ |
| 130 | 2002 | James R. Tobin(4,5) President and Chief Executive Officer | 795.0K | 795.4K | — | — | — | 61.0K | 1.65M | 0.00% | ↗ |
| 131 | 2002 | Lawrence C. Best Executive Vice President — Finance & Administration and Chief Financial Officer | 550.0K | 541.7K | — | 120.0K | — | 33.8K | 1.25M | 9.63% | ↗ |
| 132 | 2002 | Lawrence C. Best Senior Vice President — Finance & Administration and Chief Financial Officer | 550.0K | 541.7K | — | 120.0K | — | 8.8K | 1.22M | 9.83% | ↗ |
| 133 | 2002 | Paul A. LaViolette Chief Operating Officer | 428.1K | 404.8K | — | 120.0K | — | 49.7K | 1.00M | 11.97% | ↗ |
| 134 | 2002 | Paul A. LaViolette Senior Vice President and Group President, Cardiovascular | 428.1K | 404.8K | — | 120.0K | — | 24.7K | 977.5K | 12.28% | ↗ |
| 135 | 2002 | Paul W. Sandman Executive Vice President, Secretary and General Counsel | 375.0K | 369.4K | — | 120.0K | — | 52.6K | 917.0K | 13.09% | ↗ |
| 136 | 2002 | Paul W. Sandman Senior Vice President, Secretary and General Counsel | 375.0K | 369.4K | — | 120.0K | — | 27.6K | 892.0K | 13.45% | ↗ |
| 137 | 2002 | Fredericus A. Colen Executive Vice President and Chief Technology Officer | 350.0K | 344.6K | — | 120.0K | — | 62.6K | 877.2K | 13.68% | ↗ |
| 138 | 2002 | Fredericus A. Colen Senior Vice President and Chief Technology Officer | 350.0K | 344.6K | — | 120.0K | — | 37.6K | 852.2K | 14.08% | ↗ |
| 139 | 2001 | James R. Tobin(4,5) President and Chief Executive Officer | 763.1K | 610.0K | — | 90.0K | — | 10.3K | 1.47M | 6.11% | ↗ |
| 140 | 2001 | James R. Tobin President and Chief Executive Officer | 763.1K | 610.0K | — | 45.0K | — | 10.3K | 1.43M | 3.15% | ↗ |
| 141 | 2001 | Peter M. Nicholas Founder and Chairman of the Board | 700.0K | 491.0K | — | 35.0K | — | 74.8K | 1.30M | 2.69% | ↗ |
| 142 | 2001 | Paul A. LaViolette Senior Vice President and Group President, Cardiovascular | 400.0K | 390.3K | — | 60.0K | — | 24.6K | 875.0K | 6.86% | ↗ |
| 143 | 2001 | Lawrence C. Best Senior Vice President — Finance & Administration and Chief Financial Officer | 435.0K | 369.1K | — | 60.0K | — | 7.9K | 872.0K | 6.88% | ↗ |
| 144 | 2001 | Lawrence C. Best Senior Vice President—Finance & Administration and Chief Financial Officer | 435.0K | 369.1K | — | 30.0K | — | 7.9K | 842.0K | 3.56% | ↗ |
| 145 | 2001 | Fredericus A. Colen Senior Vice President and Chief Technology Officer | 315.0K | 320.9K | — | 190.0K | — | 6.5K | 832.5K | 22.82% | ↗ |
| 146 | 2001 | Paul W. Sandman Senior Vice President, Secretary and General Counsel | 345.0K | 292.7K | — | 50.0K | — | 28.8K | 716.6K | 6.98% | ↗ |
| 147 | 2000 | James R. Tobin President and Chief Executive Officer | 730.0K | 408.8K | — | 930.0K | — | 14.7K | 2.08M | 44.64% | ↗ |
| 148 | 2000 | Lawrence C. Best Senior Vice President—Finance & Administration and Chief Financial Officer | 415.0K | 249.0K | 368.0K | 770.0K | — | 7.1K | 1.81M | 62.90% | ↗ |
| 149 | 2000 | Peter M. Nicholas Founder and Chairman of the Board | 700.0K | 392.0K | — | 572.3K | — | 87.7K | 1.75M | 32.66% | ↗ |
| 150 | 2000 | Paul A. LaViolette Senior Vice President and Group President, Cardiovascular | 385.0K | 207.9K | 368.0K | 320.0K | — | 25.4K | 1.31M | 52.67% | ↗ |
| 151 | 2000 | Paul W. Sandman Senior Vice President, Secretary and General Counsel | 326.0K | 234.7K | 368.0K | 275.0K | — | 31.7K | 1.24M | 52.04% | ↗ |
| 152 | 1999 | James R. Tobin President and Chief Executive Officer | 700.0K | 459.0K | — | 1.00M | — | 7.4K | 2.17M | 46.16% | ↗ |
| 153 | 1999 | Peter M. Nicholas Founder and Chairman of the Board | 747.0K | 590.9K | — | — | — | 99.7K | 1.44M | 0.00% | ↗ |
| 154 | 1999 | Lawrence C. Best Senior Vice President—Finance & Administration and Chief Financial Officer | 397.0K | 235.3K | — | 20.0K | — | 6.5K | 658.7K | 3.04% | ↗ |
| 155 | 1999 | Paul A. LaViolette Senior Vice President and Group President, Cardiovascular | 320.0K | 225.0K | — | 40.0K | — | 26.5K | 611.5K | 6.54% | ↗ |
| 156 | 1999 | Paul W. Sandman Senior Vice President, Secretary and General Counsel | 312.0K | 184.9K | — | 20.0K | — | 35.0K | 551.8K | 3.62% | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Michael F. Mahoney | Chairman, President & Chief Executive Officer | 6M | male |
| Joseph Fitzgerald | Executive VP & Group President of Cardiovascular | 2M | male |
| Arthur Crosswell Butcher | Executive Vice President and Group President of MedSurg & Asia Pacific | 2M | male |
| Vance R. Brown | EVP, General Counsel & Corporate Secretary | 2M | male |
| Jonathan Monson | Executive Vice President & Chief Financial Officer | 1M | male |
| Emily Woodworth | Senior Vice President, Global Controller & Chief Accounting Officer | — | female |
| Brenda Becker | Senior Vice President of Global Government Affairs | — | female |
| Miriam O'sullivan | Senior Vice President & Chief Human Resources Officer | — | female |
| Paudie O'Connor | Executive Vice President of Global Operations | — | male |
| Adam Smith | General Manager of Global Sales & Marketing | — | male |
ESG Rating
ESG Score History MEDICAL - DEVICES
Benchmark vs Sector
Political Trading Activity (25M)
Senate Trading Activity
| Transaction Date | Disclosed | Senator | State | Owner | Type | Amount | Link |
|---|---|---|---|---|---|---|---|
| 2025-12-29 | 2026-01-16 | Markwayne Mullin | OK | Joint | Purchase | $15,001 - $50,000 | ↗ |
| 2025-12-17 | 2026-01-13 | John Boozman | AR | Joint | Sale (Partial) | $1,001 - $15,000 | ↗ |
| 2025-12-17 | 2026-01-13 | John Boozman | AR | Joint | Sale | $1,001 - $15,000 | ↗ |
| 2025-02-13 | 2025-03-06 | John Boozman | AR | Joint | Purchase | $1,001 - $15,000 | ↗ |
| 2023-10-03 | 2023-11-01 | Markwayne Mullin | OK | Joint | Purchase | $1,001 - $15,000 | ↗ |
| 2023-09-13 | 2023-10-12 | Markwayne Mullin | OK | Joint | Purchase | $15,001 - $50,000 | ↗ |
House Trading Activity
| Transaction Date | Disclosed | Representative | District | Owner | Type | Amount | Link |
|---|---|---|---|---|---|---|---|
| 2026-03-30 | 2026-04-09 | Ro Khanna | CA17 | — | Purchase | $15,001 - $50,000 | ↗ |
| 2026-03-27 | 2026-04-10 | Michael McCaul | TX10 | Spouse | Purchase | $1,001 - $15,000 | ↗ |
| 2026-02-10 | 2026-03-10 | Gilbert Cisneros | CA31 | — | Purchase | $1,001 - $15,000 | ↗ |
| 2026-01-30 | 2026-02-13 | Gilbert Cisneros | CA31 | — | Purchase | $1,001 - $15,000 | ↗ |
| 2025-12-24 | 2026-01-12 | Gilbert Cisneros | CA31 | — | Sale (Partial) | $1,001 - $15,000 | ↗ |
| 2025-11-18 | 2025-12-15 | Gilbert Cisneros | CA31 | — | Purchase | $1,001 - $15,000 | ↗ |
| 2025-10-28 | 2025-11-17 | Kevin Hern | OK01 | Joint | Sale | $15,001 - $50,000 | ↗ |
| 2025-10-17 | 2025-11-18 | Gilbert Cisneros | CA31 | — | Purchase | $1,001 - $15,000 | ↗ |
| 2025-10-07 | 2025-11-14 | Ro Khanna | CA17 | Spouse | Sale | $1,001 - $15,000 | ↗ |
| 2025-09-23 | 2025-10-10 | Valerie Hoyle | OR04 | Spouse | Sale (Full) | $1,001 - $15,000 | ↗ |
| 2025-08-04 | 2025-09-15 | Lisa McClain | MI09 | Spouse | Sale | $1,001 - $15,000 | ↗ |
| 2025-07-31 | 2025-08-15 | Gilbert Cisneros | CA31 | — | Sale | $1,001 - $15,000 | ↗ |
| 2025-06-26 | 2025-07-11 | Gilbert Cisneros | CA31 | — | Sale | $1,001 - $15,000 | ↗ |
| 2025-06-11 | 2025-07-11 | Gilbert Cisneros | CA31 | — | Sale | $1,001 - $15,000 | ↗ |
| 2025-05-13 | 2025-06-06 | Gilbert Cisneros | CA31 | — | Sale (Partial) | $1,001 - $15,000 | ↗ |
| 2025-05-13 | 2025-06-09 | Gilbert Cisneros | CA31 | — | Sale | $1,001 - $15,000 | ↗ |
| 2025-05-12 | 2025-06-23 | Jefferson Shreve | IN06 | — | Sale | $15,001 - $50,000 | ↗ |
| 2025-04-28 | 2025-05-07 | Gilbert Cisneros | CA31 | — | Sale | $1,001 - $15,000 | ↗ |
| 2025-04-21 | 2025-05-13 | Bruce Westerman | AR04 | — | Sale | $1,001 - $15,000 | ↗ |
| 2025-03-17 | 2025-04-07 | Gilbert Cisneros | CA31 | — | Sale (Partial) | $1,001 - $15,000 | ↗ |
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for BSX
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
